LY6D (lymphocyte antigen 6 family member D) is a GPI-anchored cell surface protein with multiple roles in immune development and cancer biology. In normal development, LY6D marks early lymphoid progenitor commitment, particularly in plasmacytoid dendritic cell (pDC) lineage specification where SiglecH+Ly6D+ precursors define pDC differentiation along the IL-7R+ lymphoid branch 1. In disease contexts, LY6D functions as a marker of cancer stem cells and tumor-initiating populations across multiple malignancies. In pancreatic ductal adenocarcinoma, LY6D+ cells represent a distinct gastric-like stem cell state that emerges early during tumor initiation and persists throughout progression; mechanistically, LY6D scaffolds lipid raft-associated kinase networks driving FOSL1-dependent epigenetic reprogramming 2. In extrahepatic cholangiocarcinoma, basal-like LY6D+ cancer cells display stemness, drug resistance, and interferon-responsive features sustained by ISG15-enriched microenvironments 3. LY6D is upregulated in laryngeal squamous cell carcinoma where it correlates with chemoresistance to multiple agents and lymph node metastasis 4. In inflammatory conditions, IL-1β induces LY6D+ club cell transdifferentiation that promotes neutrophil recruitment in chr8 rhinosinusitis with nasal polyps 5. Additionally, LY6D serves as a biomarker in cancer diagnosis and correlates with poor prognosis 67, while its expression is regulated by the YB-1-KLF5 axis in basal-like breast cancer 8.